TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, has announced the publication of a peer-reviewed article in the journal Cancers detailing preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The findings highlight the potential of TTX-MC138 to address a critical unmet need in metastatic disease, where current treatment options remain limited and prognosis is poor.
The study demonstrated that TTX-MC138, when administered systemically, accumulated in metastatic bone lesions and effectively reduced the expression of microRNA-10b (miR-10b), a key driver of metastasis. This reduction led to increased expression of the downstream tumor-suppressor target HOXD10, a mechanism that is believed to inhibit the metastatic cascade. Importantly, the treatment produced significant survival benefits compared to control groups, with repeated dosing being well tolerated and showing no observed systemic toxicity.
These results provide further validation of TransCode's proprietary oligonucleotide nanotechnology platform, which is designed to specifically target and inhibit miR-10b. The findings also suggest that TTX-MC138 may have applicability across additional metastatic disease settings, broadening its potential impact beyond breast cancer bone metastasis. According to the company, the study reinforces the scientific rationale for targeting miR-10b as a therapeutic strategy against metastatic cancers.
TransCode Therapeutics is a clinical-stage company focused on developing RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, is being developed to treat metastatic tumors that overexpress miR-10b, a well-documented biomarker of metastasis. The company's pipeline also includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The publication in Cancers adds to the growing body of evidence supporting TTX-MC138's potential as a novel anti-metastatic therapy. Metastatic bone disease is a common complication of advanced breast cancer, often leading to severe pain, fractures, and reduced quality of life. Current treatments are largely palliative, underscoring the need for therapies that can directly target and inhibit the spread of cancer cells.
These promising preclinical results underscore the importance of continued research into RNA-based approaches for cancer treatment. As TransCode advances TTX-MC138 toward clinical development, the outcomes of this study could have significant implications for patients with metastatic cancers, potentially offering a new avenue for treatment where options are currently limited.
